These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 3039806)

  • 21. The detection and inhibition of proteolytic enzyme activity in concentrated preparations of inactivated foot-and-mouth disease virus.
    Doel TR; Collen T
    J Biol Stand; 1983 Jan; 11(1):35-46. PubMed ID: 6300129
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Innocuity testing of foot-and-mouth disease vaccines. II. Aziridine-inactivated antigen produced in baby hamster kidney cells.
    Barteling SJ
    J Biol Stand; 1983 Oct; 11(4):305-12. PubMed ID: 6315737
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhancement of immunizing potency of a foot-and-mouth disease vaccine for cattle by treatment of the antigen with formaldehyde.
    Mowat GN; Masters RC; Prince MJ
    Arch Gesamte Virusforsch; 1973; 41(4):365-70. PubMed ID: 4354238
    [No Abstract]   [Full Text] [Related]  

  • 24. Comparison between in vitro neutralization titres and in vivo protection against homologous and heterologous challenge induced by vaccines prepared from two serologically distinct variants of foot-and-mouth disease virus, serotype A22.
    Bolwell C; Parry NR; Rowlands DJ
    J Gen Virol; 1992 Mar; 73 ( Pt 3)():727-31. PubMed ID: 1312129
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of a methodology for the production of foot- and- mouth disease virus from BHK21 C13 monolayer cells grown in a 100 l (20 m2) glass sphere propagator.
    Whiteside JP; Whiting BR; Spier RE
    Dev Biol Stand; 1979; 42():113-9. PubMed ID: 223915
    [No Abstract]   [Full Text] [Related]  

  • 26. Plaque production by carrier strains of foot-and-mouth disease virus in BHK-monolayers incubated at different temperatures.
    Straver PJ; van Bekkum JG
    Arch Gesamte Virusforsch; 1972; 37(1):12-8. PubMed ID: 4336959
    [No Abstract]   [Full Text] [Related]  

  • 27. Binary ethylenimine as an inactivant for foot-and-mouth disease virus and its application for vaccine production.
    Bahnemann HG
    Arch Virol; 1975; 47(1):47-56. PubMed ID: 167679
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Proceedings: Quantitative assay of the immunizing dose of monovalent vaccines against foot-and-mouth disease prepared from the virus propagated on cattle tongue mucosa and in culture after Frenkel.
    Wiśniewski J; Kobusiewicz T; Szkilnik S; Baranowski C; Jankowska J; Labecka W
    Acta Microbiol Pol A; 1974; 6(1):131. PubMed ID: 4364054
    [No Abstract]   [Full Text] [Related]  

  • 29. The potential of recombination for the production of foot-and-mouth disease virus vaccine strains.
    McCahon D; King AM; Slade WR; Skinner HH; Haresnape J
    Dev Biol Stand; 1980; 46():223-30. PubMed ID: 6244999
    [TBL] [Abstract][Full Text] [Related]  

  • 30. One year experience on the Lindholm B medium used in large--scale FMD virus production on BHK cells in suspension.
    Jensen MH; Soerensen FO
    Dev Biol Stand; 1976; 35():45-53. PubMed ID: 198312
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunogenicity of foot-and-mouth disease virus grown in BHK-21 suspension cells. Correlation with cell ploidy alterations and abnormal expression of the alpha 5 beta 1 integrin.
    Amadori M; Berneri C; Archetti IL
    Vaccine; 1994 Feb; 12(2):159-66. PubMed ID: 7511862
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Attenuation of foot-and-mouth disease virus by chemical means.
    Maes R
    Arch Gesamte Virusforsch; 1970; 29(1):63-76. PubMed ID: 4318111
    [No Abstract]   [Full Text] [Related]  

  • 33. Genotypic and phenotypic changes of BHK-21 cells grown in suspension cultures.
    Amadori M; Berneri C
    Cytotechnology; 1993; 11 Suppl 1():S106-8. PubMed ID: 7686770
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Haemagglutination by type SAT 2 foot-and-mouth disease viruses.
    Booth JC; Pay TW
    J Gen Virol; 1973 Jun; 19(3):397-404. PubMed ID: 4353214
    [No Abstract]   [Full Text] [Related]  

  • 35. [Purification of viral suspensions obtained from antigens and BHK cells].
    Berson JP; Giraud M; Durand M; Prunet P
    C R Acad Hebd Seances Acad Sci D; 1970 Apr; 270(15):1950-3. PubMed ID: 4987733
    [No Abstract]   [Full Text] [Related]  

  • 36. [Laboratory trials of culturing BHK 21 C 13 cells in a roller using an enzymatic egg hydrolysate-based nutrient medium].
    Veleva E; Genov I; Stefanova L; Tekerlekov P; Tivchev G
    Vet Med Nauki; 1980; 17(9-10):37-42. PubMed ID: 6266126
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Developments in foot-and-mouth disease vaccines.
    Barteling SJ; Vreeswijk J
    Vaccine; 1991 Feb; 9(2):75-88. PubMed ID: 1647575
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The development of an attenuated foot-and-mouth disease virus vaccine by modification and cloning in tissue cultures of BHK21 cells.
    Mowat GN; Barr DA; Bennett JH
    Arch Gesamte Virusforsch; 1969; 26(4):341-54. PubMed ID: 4306372
    [No Abstract]   [Full Text] [Related]  

  • 39. Fast modification of foot-and-mouth disease virus by selecting clones in bovines.
    Bernal C; Balestrini J; Gomez G; Castañeda J
    Dev Biol Stand; 1976; 35():471-9. PubMed ID: 198313
    [No Abstract]   [Full Text] [Related]  

  • 40. Immunization of guinea pigs with foot-and-mouth disease virus subjected to photodynamic inactivation.
    Espensen L
    Acta Pathol Microbiol Scand; 1966; 68(4):585-91. PubMed ID: 4289502
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.